



#10/B
4-3-02
NW

PATENT

Attorney Docket 044508-5001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Gerald Quinnan *et al.***

Application No. **09/762,261**

Filed: **May 29, 2001**

For: **Expression and Characterization of HIV-1
Envelope Protein Associated With a Broadly
Reactive Neutralizing Antibody Response**

Group Art Unit: 1648

Examiner: **Shanon Foley**

RECEIVED
APR 02 2002
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT & AMENDMENT UNDER 37 C.F.R. 1.115

In response to the Restriction Requirement dated January 30, 2002 (Paper No. 7), the period for response having been extended from February 28, 2002 to March 30, 2002 by payment of a one-month extension of time, please amend the above-referenced application as follows:

In the Claims:

Please cancel claim 1 without prejudice or disclaimer of Applicants' right to file divisional applications containing the subject matter of this claim and amend claims 5-9, 12, 16-17 and 19-20 as follows:

Please amend claim 5-9, 12, 16-17 & 19-20 as follows:

5. (Once Amended) A vaccine composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 2-4 and a pharmaceutically acceptable carrier.

6. (Once Amended) An immunogenic composition comprising an isolated HIV-1 envelope protein or fragment thereof of any one of claims 2-4 and a pharmaceutically acceptable carrier.

7. (Once Amended) An isolated nucleic acid molecule encoding the HIV-1 envelope protein or fragment thereof of any of claims 2-4.

8. (Once Amended) A fusion protein comprising all or a portion of a microbiological antigen into which any one of the proteins of claims 2-4 has been inserted.

B1